Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Implications of siRNA Therapy in Bone Health: Silencing Communicates

Sirna Therapy for Cancer and Non-Lethal Diseases Such As Arthritis and Osteoporosis

siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis.

siRNA therapeutics: insights, challenges, remedies and future prospects

siRNA therapy in osteoarthritis: targeting cellular pathways for advanced treatment approaches

Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer

Insights on prospects of nano-siRNA based approaches in treatment of Cancer

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles

Nucleic acids based integrated macromolecular complexes for SiRNA delivery: Recent advancements

Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine

Recent advancements in small interfering RNA based therapeutic approach on breast cancer

Designing biomaterials for the delivery of RNA therapeutics to stimulate bone healing

Recent Developments in Bone Anabolic Therapy for Osteoporosis

Engineering siRNA therapeutics: challenges and strategies

A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications

The current state and future directions of RNAi-based therapeutics

RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA